HC Wainwright Has Negative View of Disc Medicine Q1 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Stock analysts at HC Wainwright cut their Q1 2026 earnings estimates for shares of Disc Medicine in a research note issued to investors on Tuesday, February 17th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($1.63) for the quarter, down from their prior estimate of ($1.56). The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. HC Wainwright also issued estimates for Disc Medicine’s Q2 2026 earnings at ($1.67) EPS, Q3 2026 earnings at ($1.74) EPS, Q4 2026 earnings at ($1.83) EPS, FY2026 earnings at ($6.88) EPS, FY2027 earnings at ($6.83) EPS, FY2028 earnings at ($5.27) EPS, FY2029 earnings at $0.57 EPS and FY2030 earnings at $7.08 EPS.

Other research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, January 21st. Truist Financial upped their target price on Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, November 10th. UBS Group restated an “overweight” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Stifel Nicolaus cut their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Cantor Fitzgerald reduced their price target on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and an average target price of $104.82.

Disc Medicine Stock Performance

Shares of IRON opened at $61.36 on Thursday. Disc Medicine has a 12 month low of $30.82 and a 12 month high of $99.50. The stock has a fifty day moving average price of $76.63 and a 200-day moving average price of $75.14. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. The firm has a market cap of $2.32 billion, a PE ratio of -11.47 and a beta of 0.88.

Insider Activity

In related news, CFO Jean M. Franchi sold 7,081 shares of Disc Medicine stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $65.47, for a total value of $463,593.07. Following the sale, the chief financial officer directly owned 71,343 shares in the company, valued at approximately $4,670,826.21. The trade was a 9.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Kevin Bitterman sold 68,923 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $91.24, for a total value of $6,288,534.52. Following the transaction, the director directly owned 14,161 shares of the company’s stock, valued at $1,292,049.64. The trade was a 82.96% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 284,761 shares of company stock worth $24,913,484. Company insiders own 3.64% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. lifted its stake in shares of Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after purchasing an additional 399,026 shares during the period. Vanguard Group Inc. grew its position in Disc Medicine by 22.1% during the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after buying an additional 319,621 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Disc Medicine by 28.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock valued at $134,839,000 after buying an additional 371,576 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after acquiring an additional 828,248 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of Disc Medicine by 7.7% during the 4th quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company’s stock valued at $120,566,000 after acquiring an additional 108,197 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

Key Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Institutional buying — large funds (JPMorgan, BVF, Jennison, Perceptive, RA Capital) added or established sizable positions in Q4, showing continued institutional interest that can underpin liquidity and longer‑term support. MarketBeat IRON – institutional trading
• Positive Sentiment: Cantor Fitzgerald buy rating remains — at least one buy‑side analyst maintained/affirmed a constructive view, which may limit downside if pipeline updates turn positive. Disc Medicine (IRON) Receives a Buy from Cantor Fitzgerald
• Neutral Sentiment: Company will pursue standard U.S. approval after FDA denied a fast‑track designation — keeps the program alive but implies a longer, less certain path to market. Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod
• Neutral Sentiment: Reported short‑interest shows zero shares / 0.0 days‑to‑cover — this is almost certainly a data/reporting anomaly and not meaningful evidence of changed short pressure. (No article link available.)
• Negative Sentiment: Regulatory setback — coverage highlights an FDA Complete Response Letter (CRL) that raises questions about the APOLLO study and the lead bitopertin program; this is the primary near‑term negative catalyst. Disc Medicine: Downgrading As CRL Puts APOLLO Study Into Question Valuation Check After FDA Complete Response Letter
• Negative Sentiment: Insider selling — CFO Jean Franchi disclosed multiple recent sales (e.g., 4,075 and 7,081 shares) and other insiders (including John Quisel) sold shares recently; concentrated insider selling can spook shorter‑term holders. SEC Filing – Insider Transactions Disc Medicine Insider Sells John Quisel Sells 13,264 Shares
• Negative Sentiment: Shareholder litigation risk — Pomerantz LLP has opened an investor investigation which raises the prospect of lawsuits or disclosures that could add legal and reputational risk. Pomerantz investor alert
• Negative Sentiment: Analyst cuts and target trims — HC Wainwright lowered multi‑quarter and multi‑year EPS forecasts and Wells Fargo and BMO reduced targets/expectations, increasing downward pressure on consensus valuation. MarketBeat IRON – analyst note summary BMO Lowers Expectations for Disc Medicine Wells Fargo Lowers Disc Medicine Price Target

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.